Mateon Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on developing novel treatments for solid tumor cancers. The company’s primary business activity is the formulation and clinical evaluation of locally delivered chemotherapeutic agents designed to achieve high intratumoral concentrations while minimizing systemic toxicity. By leveraging proprietary hydrogel and topical delivery platforms, Mateon aims to address cancers in the brain, skin and other localized sites.
Among its key product candidates is OncoGel®, a biodegradable gel formulation of paclitaxel that has been studied for the treatment of brain tumors and esophageal cancer, enabling sustained, site‐specific drug release. Mateon has also advanced Cicadermer™, a novel topical formulation of 5‐fluorouracil intended for the treatment of non‐melanoma skin cancers such as basal cell carcinoma. In addition, the company holds an exclusive license for Triapine®, a ribonucleotide reductase inhibitor, which is under investigation in combination regimens for hematologic malignancies and solid tumors.
Founded in California, Mateon has conducted multiple Phase I and II clinical trials across North America and Europe, collaborating with leading academic medical centers and oncology research networks. The company’s development strategy emphasizes rigorous design of proof‐of‐concept studies and strategic partnerships to advance candidates through pivotal trials. Over the years, Mateon has built a robust intellectual property portfolio covering its delivery technologies and therapeutic formulations.
Headquartered in San Diego, California, Mateon Therapeutics is led by a management team with deep experience in oncology drug development, clinical operations and regulatory affairs. Its board of directors and scientific advisory members bring expertise from large pharmaceutical firms, academic institutions and biotech startups, guiding the company’s efforts to deliver locally administered cancer therapies that improve patient outcomes.
AI Generated. May Contain Errors.
Free MATN Stock Alerts